Evgen Pharma plc (EVG) is a leading biotechnology business based in the UK. It opened the day at 9.5p after a previous close of 9.55p. During the day the price has varied from a low of 9.5p to a high of 10.2p. The latest price was 10.2p (25 minute delay). Evgen Pharma is listed on the London Stock Exchange (LSE) and employs 9 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Evgen Pharma's share price has had significant positive movement.
Its last market close was 14.2p, which is 64.44% up on its pre-crash value of 5.05p and 468.00% up on the lowest point reached during the March crash when the shares fell as low as 2.5p.
If you had bought £1,000 worth of Evgen Pharma shares at the start of February 2020, those shares would have been worth £684.21 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £2,989.47.
|52-week range||2.5p - 15.8999p|
|50-day moving average||8.9801p|
|200-day moving average||11.0808p|
|Wall St. target price||113p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-2.7p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-08)||-3.77%|
|1 month (2020-12-18)||10.2|
|3 months (2020-10-16)||-23.60%|
|6 months (2020-07-17)||9.09%|
|1 year (2020-01-17)||53.38%|
|2 years (2019-01-17)||-34.30%|
|3 years (2018-01-17)||-34.19%|
|5 years (2016-01-15)||-54.16%|
|Gross profit TTM||£0|
|Return on assets TTM||-49.72%|
|Return on equity TTM||-75.87%|
|Market capitalisation||£15.4 million|
TTM: trailing 12 months
We're not expecting Evgen Pharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Evgen Pharma's shares have ranged in value from as little as 2.5p up to 15.8999p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Evgen Pharma's is 1.478. This would suggest that Evgen Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.